Myositis

Quick Links

For Healthcare Professionals

Background

The idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of multisystem autoimmune diseases, also referred to as ‘myositis spectrum disorders’ or ‘myositis’, affecting 19 adults per million person-years and 4 children per million person-years.

IIM traditionally encompasses polymyositis, dermatomyositis, juvenile dermatomyositis and inclusion body myositis. More recently, immune-mediated necrotising myopathy, anti-synthetase syndrome and connective tissue disease-overlap disorders have become recognised as distinct clinical entities within the label of IIM-spectrum disease

Patients with IIM can experience significant negative impacts on quality of life. This occurs from skeletal muscle inflammation and consequent weakness, and extra-muscular manifestations including skin disease, gastrointestinal involvement, interstitial lung disease and cardiac involvement.

Symptoms may include muscle weakness, pain, fatigue, rashes and shortness of breath. A specialist referral is needed to confirm the diagnosis and start treatment. The specialist may arrange for bloods, electrical muscle tests, magnetic resonance imaging muscle scans, and muscle biopsy.

Unfortunately, many patients with IIM experience aggressive or treatment-resistant disease, and organ damage can occur, causing disability. Side effects from medications, particularly steroids, are common and can be serious. New treatment options are becoming available, including ‘biologic’ – drugs manufactured from living proteins. Biologics are more effective than steroids and have a better side effect profile. One example is rituximab, however access to this drug is variable, not all patients are eligible and some don’t respond.

We need better tools to help us predict which patients with IIM will best respond to the right treatments.

Quick Links

Client 1
Client 1
Client 1
Client 1